FBLG

Accepted Patent Contains Claims Covering Methods of Combining Fibroblasts, Platelet Rich Plasma, and Nucleus Pulposus Conditioned Media to Regenerate Cartilage and Improve the Condition of Degenerated and Aged DiscsHOUSTON, Oct. 14, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that IP Australia has issued a Notice of Acceptance for Australian Patent Application No. 2024200985, titled "Cellular Blend for the Regeneration of Chondrocy

POS AM - FibroBiologics, Inc. (0001958777) (Filer)

POS AM - FibroBiologics, Inc. (0001958777) (Filer)

D - FibroBiologics, Inc. (0001958777) (Filer)

8-K - FibroBiologics, Inc. (0001958777) (Filer)

New approach proposes an alternative to repeated injectionsHOUSTON, Oct. 7, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced today that it has filed a U.S. patent application covering a new cell-based technology designed to continuously produce peptides such as GLP-1, GIP and GLP-2 inside the body.Today, popular GLP-1 medicines used for weight loss and diabetes generally require patients to take regular weekly injections or daily pills. Fibro

Newly Granted Patent Covers Methods of Augmenting the Regenerative Efficacy of Fibroblasts Using Platelet Rich Plasma and Cytokines, with Claims Directed to Angiogenesis and Spinal Disc RegenerationHOUSTON, Sept. 29, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the European Patent Office has granted European Patent No. 3568465, titled "Methods of Enhancing Fibroblast Therapeutic Activity." The patent covers met

8-K - FibroBiologics, Inc. (0001958777) (Filer)

HOUSTON, Sept. 17, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the closing of a private placement on September 15, 2026, with Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics, for the purchase of 298,508 shares of common stock and accompanying warrants to purchase up to 298,508 shares of common stock, priced at-the-market under Nasdaq rules.

D - FibroBiologics, Inc. (0001958777) (Filer)

4 - FibroBiologics, Inc. (0001958777) (Issuer)

8-K - FibroBiologics, Inc. (0001958777) (Filer)

DEFA14A - FibroBiologics, Inc. (0001958777) (Filer)

Newly Issued Patent Covers Topical Administration of 3D Spheroid Fibroblasts and Fibroblast-Derived Materials to Treat and Accelerate the Healing of WoundsHOUSTON, Sept. 3, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,721,866, titled "Therapeutic Use of Fibroblasts for Use in Wound Healing." The patent, issued on September 1, 2026, covers method

3 - FibroBiologics, Inc. (0001958777) (Issuer)

Newly Issued Patent Covers Methods of Promoting Disc Regeneration Using Components Derived from Stimulated FibroblastsHOUSTON, Sept. 1, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,716,055, titled "Treatment of Disc Degenerative Disease and Stimulation of Proteoglycan Synthesis by Fibroblast Conditioned Media and Formulations Th

HOUSTON, Aug. 27, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the release of the third batch of its CYWC628 drug product and its shipment to Australia in support of the ongoing Phase 1/2 clinical trial in patients with diabetic foot ulcers (DFUs). The batch was manufactured in accordance with current Good Manufacturing Practices (cGMP) and has successfully passed all required safety and quality testing, enabling it

HOUSTON, Aug. 26, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that it received confirmation from The Nasdaq Stock Market LLC ("Nasdaq") on August 25, 2026, informing the Company that it has regained compliance with the bid price requirement in Listing Rule 5550(a)(2). The Company is now in compliance with all Nasdaq listing standards, and its common s

8-K - FibroBiologics, Inc. (0001958777) (Filer)

Legendary Sports Agent, Attorney, and Longtime Advocate for Human Longevity and Brain Health Joins BoardHOUSTON, Aug. 24, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the appointment of Leigh Steinberg to its Board of Directors. Widely regarded as the most influential sports agent of his generation, Mr. Steinberg brings five decades of dealmaking experience, a deep commitment to human longevity research, and a long record of initiat

Patent covers the use of cannabidiol in combination with fibroblast-based cell therapy to treat degenerative disc diseaseHOUSTON, Aug. 20, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the acceptance by IP Australia of Australian Patent Application No. 2020368344, entitled "Cannabidiol Adjuvant Therapy for Treatment of Disc Degenerative Disease." The accepted application describes methods of treating degenerative disc disease by admi

Animal trials show cartilage repair within four weeks following a single injection of chondrocyte spheroidsHOUSTON, Aug. 18, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced a breakthrough in its orthopedics laboratory using chondrocyte spheroids to treat degenerative joints. Degenerative joint disease affects millions of people worldwide and is one of the leading causes o

SCHEDULE 13G - FibroBiologics, Inc. (0001958777) (Subject)

Patent has potential for applications beyond diabetes, including other cell and tissue transplantation proceduresHOUSTON, Aug. 11, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,691,147, entitled "Methods and Compositions for Treatment of Type 1 Diabetes Using Fibroblasts in Facilitation of Islet Engraftment." The patent describes methods utilizin

Granted claims cover Sox9-based conversion of fibroblasts into cartilage-producing cells, supporting the Company's orthopedics and degenerative disc pathwaysHOUSTON, Aug. 5, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the European Patent Office (EPO) has granted the Company's patent entitled "Gene Therapy for the Regeneration of Chondrocytes or Cartilage Type Cells."